Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05129241
Other study ID # OBS17242
Secondary ID U1111-1265-6221
Status Completed
Phase
First received
Last updated
Start date November 18, 2021
Est. completion date February 16, 2023

Study information

Verified date March 2023
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Primary objectives: - To assess the effectiveness of the PRALUENT® 2 ml SYDNEY auto-injector as measured by the lipid-lowering effect of alirocumab after approx. 12 weeks treatment - To assess the treatment satisfaction, as well as patient adherence and persistence after approximately 12 weeks of treatment with the PRALUENT® 2 ml SYDNEY auto-injector Secondary objective: Safety and tolerability


Description:

Study duration per participant is approximately 12 weeks


Recruitment information / eligibility

Status Completed
Enrollment 163
Est. completion date February 16, 2023
Est. primary completion date February 16, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Primary hypercholesterolaemia (heterozygous familial or non-familial) or mixed dyslipidaemia AND confirmed vascular disease(*) AND other regular risk factors(**), OR confirmed familial heterozygous hypercholesterolaemia - Documented maximum dietary and drug lipid-lowering therapy within the last 12 months - Inadequate reduction of low-density lipoprotein cholesterol (LDL-C) despite maximum possible dietary and lipid-lowering therapy - The decision of the treating physician to use the PRALUENT® 2 ml SYDNEY auto-injector regardless of study enrolment - No previous therapy with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor OR prior treatment with a PCSK9 inhibitor every 2 weeks (Q2W) or monthly (Q4W) - Signed Informed Consent Form (*) Coronary heart disease (CHD), cerebrovascular manifestation, peripheral arterial occlusive disease (PAOD) (**) For cardiovascular events (e.g. diabetes mellitus, renal function glomerular filtration rate (GFR) < 60 ml/min) Exclusion Criteria: - Planned or existing pregnancy, cancer, drug or alcohol abuse, dementia, or general inability to understand the content of the observational study - Existing treatment by lipid apheresis - Age < 18 years - Contraindications to treatment with alirocumab (PRALUENT®) according to the SmPC - Current participation in a clinical study The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Germany Investigational Site Number Germany

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Absolute change from baseline to week 12 in low-density lipoprotein cholesterol (LDL-C) from baseline to week 12
Primary Percent change from baseline to week 12 in low-density lipoprotein cholesterol (LDL-C) from baseline to week 12
Primary Treatment acceptance assessed using the Injection Treatment Acceptance Questionnaire (ITAQ) week 12
Secondary Number of patients with adverse events up to 12 weeks
Secondary Number of quality defects assessed using product complaints up to 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT01572259 - Assessment of the Role of the Growth Hormone (GH) Onthe Intestinal Triglyceride-rich-lipoproteins (TRL) Metabolism Phase 3
Completed NCT05792787 - Association Between Apical Periodontitis and Atherosclerotic Cardiovascular Diseases
Completed NCT03911284 - The Learning Registry
Recruiting NCT06048588 - YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis Phase 1/Phase 2
Active, not recruiting NCT03705234 - A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease Phase 3
Completed NCT03096288 - Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity Phase 4
Enrolling by invitation NCT05485961 - Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis Phase 2/Phase 3
Completed NCT01663402 - ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab Phase 3
Completed NCT03597412 - Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM Phase 4
Completed NCT05974345 - In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Active, not recruiting NCT05030428 - Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease Phase 3
Completed NCT00185185 - Olmesartan Medoxomil in Atherosclerosis Phase 3
Completed NCT02991118 - Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk Phase 3
Completed NCT05639244 - Time Restricted Eating and Innate Immunity N/A
Completed NCT02988115 - Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant Phase 3
Recruiting NCT04215237 - How Atorvastatin Affects the Gut Flora and Metabolomics? N/A
Completed NCT05355402 - A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia Phase 2
Recruiting NCT05726838 - The Belgian REAL (BE.REAL) Registry
Active, not recruiting NCT04462159 - The Young Heart Study N/A
Not yet recruiting NCT03505073 - Association Between Dietary Habits and Risk Factors for Atherosclerotic Cardiovascular Diseases in Assiut Governorate